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We report the changed levels of serum amyloid alpha, an immunologically active protein,
in Parkinson’s disease (PD) patients’ peripheral tissues. We have previously shown that
Saa-1 and -2 (serum amyloid alpha-1,-2, genes) were among the top downregulated
genes in PD patients’ skin, using whole-genome RNA sequencing. In the current
study, we characterized the gene and protein expression profiles of skin and blood
samples from patients with confirmed PD diagnosis and age/sex matched controls.
qRT-PCR analysis of PD skin demonstrated downregulation of Saa-1 and -2 genes in
PD patients. However, the lowered amount of protein could not be visualized using
immunohistochemistry, due to low quantity of SAA (Serum Amyloid Alpha, protein) in
skin. Saa-1 and -2 expression levels in whole blood were below detection threshold
based on RNA sequencing, however significantly lowered protein levels of SAA1/2 in
PD patients’ serum were shown with ELISA, implying that SAA is secreted into the
blood. These results show that SAA is differentially expressed in the peripheral tissues
of PD patients.
Keywords: neurodegenarative disease, serum amyloid A (SAA), Parkinson’s disease (PD), intrinsically disordered
protein (IDP), skin biopsy
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by motor symptoms, like
resting tremor, hypo- and bradykinesia, rigidity and postural instability (Poewe et al., 2017).
However, the clinical specter of affected functions is much wider due to the involvement of other
central and peripheral organ systems. Pathologic neuronal lesions outside the central nervous
system (CNS) have been demonstrated in PD patients (Gelpi et al., 2014), for example characteristic
α-synuclein deposits have been found in dermal nerve fibers of PD patients skin (Wang et al., 2013).
In addition, pathogenic biomolecular defects of PD occur in non-neuronal peripheral tissues (Braak
et al., 2003; Auburger et al., 2012; Teves et al., 2018). PD patients have many dermatologic problems
like seborrhoea, seborrheic dermatitis, hyperhidrosis and impaired wound healing (Gregory and
Miller, 2015). As to date the affirmative diagnosis of PD can only be made based on the results of
post-mortem autopsy, thus there is a great need for detailed understanding of disease biology, as
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well as for studies investigating novel diagnostic and prognostic
biomarkers. Peripheral blood has been widely used in the search
for biomarkers in PD (Scherzer et al., 2007; Grünblatt et al., 2010;
Borrageiro et al., 2017), however other peripheral tissues, such
as skin, are promising models for investigating the pathogenic
mechanisms of PD.
Serum amyloid alpha (SAA) is a protein that may be
linked to PD due to its many functions in metabolic networks
affected in PD. SAA plays a key role in the functioning of the
immune system, being involved in inflammation, tumorigenesis,
regulating skin homeostasis and accumulating as misfolded AA-
amyloid protein (Artl et al., 2000; Urieli-Shoval et al., 2000).
SAA1 and SAA2 expression is induced in the liver, which is
the major site of synthesis. It is also produced extrahepatically,
especially within dermal tissues by keratinocytes (Urieli-Shoval
et al., 1998; Upragarin et al., 2005). Different types of cancers
occur less frequently in PD patients, however the risk of
melanoma is about 2-fold higher than for controls (Devine
et al., 2011; Liu et al., 2011). Serum SAA has been shown to be
elevated in melanoma patients through all stages of disease and
is proposed to be a prognostic cancer biomarker (Findeisen et al.,
2009).
The current study was undertaken based on observations from
our previous transcriptomic analysis on PD patients’ skin, which
demonstrated serum amyloid alpha 1 and 2 genes (Saa-1,-2) to
be one of the most significantly deregulated genes in PD skin
(Planken et al., 2017). It was of interest, whether the changes in
RNA levels are constant and transcribed into changed protein
levels within different tissues.
MATERIALS AND METHODS
Study Subjects
We enrolled in total 86 PD patients who were diagnosed by
neurology-board-certified movement disorders specialists and
met the Queen Square Brain Bank diagnostic criteria (Gibb
and Lees, 1988; Lees et al., 2009) from Tartu University
Hospital. 72 healthy matched controls with no personal history
of neurodegenerative diseases were also enrolled. Independent
samples of PD patients with comparable age, gender, Movement
Disorders Society’s Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS, Goetz et al., 2008) and the Hoehn and
Yahr Scale (H&Y, Hoehn and Yahr, 1967) were randomly
allocated for quantitative real time polymerase chain reaction
(qRT-PCR), enzyme-linked immunosorbent assay (ELISA) and
Immunohistochemistry. In total, the PD patients had an average
age of 71.0 ± 7.8 years, MDS-UPDRS of 52.0 ± 14.0, H&Y of
2.7 ± 0.9 and 85.0% had no family history of PD. Clinical details
of the participants are provided in Table 1 (breakdown of clinical
details of different groups in Supplementary Table S1). All PD
patients received standard medications. As a limitation to our
study, the inflammatory status of all subjects is not known, but
those tested (4 PD patients) had serum CRP< 1 mg/L and serum
cholesterol < 5.2 mmol/L. The study was approved by the local
Ethics Committee and an informed consent was obtained from
all patients and controls included in the study.
Tissue Sampling and RNA Extraction
Skin punch-biopsies of Ø 4 mm were taken from non-sun-
exposed skin from the medial side of upper arm, instantly frozen
in liquid nitrogen and stored at –80◦C until RNA extraction.
Biopsies were homogenized with Precellys24 homogenizer with
the Cryolys system (Bertin Technologies). RNeasy Fibrous Tissue
Mini Kit (Qiagen) was used for total RNA extraction, according to
the manufacturer’s protocol. During the purification on-column
DNase I was applied (Qiagen). The RNA quality was assessed
using Agilent 2100 Bioanalyzer, the RNA 6000 Nano kit (Agilent
Technologies) and the Qubit fluorometer (Life Technologies).
The lowest RIN of samples was 6.7.
Real-Time Quantitative PCR
Blood samples of 37 patients and 33 healthy controls were
obtained. Total RNA from skin biopsies was converted to
cDNA using random primers and High Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor (Applied Biosystems).
For duplex qRT-PCR analysis TaqMan Gene Expression Assays
were used: VIC (housekeeping gene ActinB) and FAM (gene
of interest) probes and TaqMan Gene R© Expression Master Mix
(Applied Biosystems). The TaqMan R© Gene Assay IDs were
the following: Hs01060665_g1 (ActinB), Hs00761940_s1 (Saa1),
Hs00754237_s1 (Saa2). qRT-PCR was performed using ABI
PRISM 7900HT Fast Real-Time PCR System equipment (Applied
Biosystems) and the ABI PRISM 7900 SDS 2.2.2 Software. Each
reaction was performed in quadruplicate to minimize technical
errors. Real-time PCR data for gene of interest was expressed
as mean 1CT value relative to housekeeping gene. 1CT of
controls was subtracted from1CT of PD to yield11CT. Relative
expression i.e. fold change was calculated using 2−1CT-function.
The data of studied genes following normal distribution were
parametrically tested by unpaired t-test.
Enzyme-Linked Immunosorbent Assay of
the Blood Samples
Blood samples of 36 patients and 27 healthy controls were
obtained. Serum was extracted from blood samples and rapidly
frozen to and stored at –80◦C. Stored samples were defrosted
and centrifuged at 1500 g at room temperature for 10 min.
ELISA kit for human SAA1/2 (Invitrogen Corporation) was used.
200-fold diluted human serum SAA1/2 standard was calibrated
to a highly purified Escherichia coli-expressed recombinant
protein. The sample measurements were performed with Tecan
GeniOS Pro luminometer in duplicate and repeated 3 times on
separate plates. Optical density (450 nm) readings were used
to quantitatively express serum SAA1/2 results. The Human
SAA1/2 concentrations for samples and controls were plotted
based on the standard curve. Values obtained for serum were
multiplied by 200 to correct for the overall dilution. The data for
mean concentration followed normal distribution, was plotted on
a barplot and parametrically tested by unpaired t-test.
Skin Immunohistochemistry
Immunohistochemistry samples were obtained from 13 PD
patients (6 male, 7 female, mean age of 72.0 ± 7.2 years) and 12
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TABLE 1 | Demographic characteristics for total PD patients and controls.
Samples PD qRT-PCR PD ELISA PD Immuno-histo HC qRT-PCR HC ELISA HC immuno-histo P
Age at enrolment (years, SD) 69.5 ± 7.3 72.1 ± 8.4 72.0 ± 7.2 72.1 ± 7.9 72.7 ± 9.6 71.8 ± 8.6 n.s.
Age of PD onset (years, SD) 61.4 ± 8.3 66.5 ± 10.8 65.6 ± 9.2 n/a n/a n/a n.s.
Male gender (n, %) 18 (49) 12 (33) 6 (46) 12 (36) 10 (37) 3(25) n.s.
1st degree relatives with PD (n, %) 3 (8.1) 4 (11.4) 0 n/a n/a n/a n.s.
MDS-UPDRS (mean, SD) 62.7 ± 24.8 71.8 ± 30.7 65.8 ± 27.1 n/a n/a n/a n.s.
H&Y (mean, SD) 2.5 ± 0.8 2.7 ± 1.0 3.1 ± 0.8 n/a n/a n/a n.s.
There were no significant (n.s.; p > 0.05) differences between independent samples by analysis of variance with post hoc Tukey test.
controls (6 male, 6 female, mean age of 71.3 ± 7.1 years). The
skin biopsies were deparaffinized with 2× 4 min. xylene, 4 min.
isopropanol, 2× 4 min. 96% alcohol. Then they were blocked with
3% hydrogen peroxide for 7 min, and processed with proteinase
K for 5 min. The slides were incubated with primary mouse
monoclonal Serum Amyloid A antibody (Novus Biologicals)
in 1:100 dilution for 30 min. and processed with detection
antibodies (DAKO REAL EnVision+Dual Link, Single Reagents,
HRP Rabbit/Mouse) for 30 min. The sections were immersed in
3.3% diaminobenzidine (Dako Company) chromogen dye and
hydrogen peroxide buffer solution for 4 min. This created a
brownish staining in the location of detection antibody. The
background was dyed with hematoxylin, dehydrated with 2x
96% alcohol and 2x xylene, covered with aqueous resin. The
immunohistochemistry visual validation procedure was carried
out by an independent pathologist. Within the publication data
1 PD patient (male, age 74) and 1 control (female, age 64) have
been presented as representative images.
RESULTS
Our previous work with skin RNA-sequencing showed a
significant downregulation of Saa-1 and -2 expression levels
in PD patients (logFC -2,75 and -1,65, respectively, Planken
et al., 2017). Further tests with 86 PD patients, who met the
Queen Square Brain Bank diagnostic criteria (Gibb and Lees,
1988; Lees et al., 2009) and 72 healthy matched controls were
performed. Saa-1 and -2 gene expression levels were measured
using qRT-PCR from skin, followed by measurement of SAA1/2
protein levels from serum using ELISA and finally the SAA1/2
protein levels were assayed using immunohistochemistry from
PD patients’ skin.
Gene Expression Profiling of Saa-1
and -2 in Skin and Blood From PD
Patients
The qRT-PCR analysis from 33 PD patients and 37 controls
demonstrated a significant 1.68-fold downregulation of Saa2
gene (p = 0.0372) and 1.34-fold downregulation of Saa1 gene
in PD patients skin, however the result was not statistically
significant (p = 0.2469) (Figure 1).
SAA Protein Visualization in the Skin
The immunohistochemical analysis of 13 PD patients’ and 12
controls’ skins for expression of SAA 1/2 protein, demonstrated
that no visually detectable protein or changes in protein levels can
be observed in PD patients (Figure 2).
ELISA From Serum
ELISA analysis (from 36 PD patients and 27 controls) of serum
for SAA 1/2 protein expression, demonstrated decreased protein
concentration levels in the serum of PD patients by 50.9%
FIGURE 1 | qRT-PCR on relative gene expression levels of Saa1 (A) and Saa2 (B) genes in the skin of 33 PD patients and 37 controls. Barplots show mean fold
changes with upper percentiles displayed in 2−1CT values. (A) Demonstrating not significantly (p = 0.25) lowered Saa1 levels in PD patients by 1.34-fold. Mean
relative gene expression for controls is 0.01001 (SEM = 0.003431) and for PD patients 0.005853 (SEM = 0.001007). (B) Demonstrating significantly (p = 0.037)
lowered Saa2 levels in PD patients by 1.68-fold. Mean relative gene expression for controls is 0.0005200 (SEM = 0.0001653) and for PD patients 0.0001749
(SEM = 4.242e-005).
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FIGURE 2 | Representative IHC for SAA 1/2. Control (A) and PD patient (B).
Magnification: 40×. Dye: Hematoxylin and immunohistochemical labeling for
serum amyloid alpha. Both in control and PD patient no detectable visual
staining can be demonstrated.
FIGURE 3 | Serum ELISA SAA1/2 concentration in 27 controls and 36 PD
patients, respectively. Demonstrating decreased concentration of SAA1/2 by
50.9% (p = 0.0021). Bars show mean concentration with upper percentiles,
66.8 µg/ml for healthy controls and 32.8 µg/ml for PD patients (p = 0.0054).
compared to controls (Figure 3, p = 0.0021), with the mean
protein concentrations being 32.8 and 66.8 µg/ml, respectively.
DISCUSSION
The qRT-PCR results of SAA downregulation in the skin
mirrored the changes obtained in RNA-sequencing (Planken
et al., 2017). Saa-1 and -2 RNA levels in whole-blood cells were
below the detection levels using RNA-sequencing (unpublished
data). In blood serum, SAA1/2 was downregulated, implying
SAA1/2 is secreted into blood. In skin immunohistochemistry,
SAA1/2 protein does not visualize, thus downregulation of the
gene is not detectable using this method. As the quantity level for
these proteins in the normal skin is physiologically low, this is to
be expected. SAA is known as a marker for AA-amyloidosis and
positive staining is seen only in patients suffering from chronic
inflammation, certain cancers or genetic defects, in which case,
the pathologic staining would be seen around basal membranes,
blood vessel walls and collagenous connective tissue (James et al.,
2011). In addition, Western blot analysis on the same subject
samples were performed, however the levels of SAA in skin
homogenates were also too low for detection (data not shown).
Taken together, the findings show downregulated Saa-1 and -2
expression in skin and protein SAA1/2 levels in blood.
SAA as an Immunomodulator in the Skin
SAA in the skin tissue is an autocrine modulatory protein,
induced by inflammatory signals like IL-11α, TNF-α, and IL-17A
and stimulating the expressions of other cytokines, interleukins
and metalloproteinases on the tissue level (Patel et al., 1998;
Furlaneto and Campa, 2000; Vallon et al., 2001; de Seny et al.,
2013). SAA upregulates its own expression, creating an autocrine
self-maintaining regulation by positive feedback (Couderc et al.,
2017). In our previous work with skin RNA-sequencing a large
set of genes in PD skin were downregulated, which are involved
in the process of epidermal cornification and desquamation
(Planken et al., 2017). The downregulation of SAA, an important
autocrine immunomodulator in PD skin, might contribute to
the impaired epidermal renewal processes which are clinically
associated with poor wound healing in PD patients. Moreover,
serum SAA has been shown to be elevated in patients of all
stages of melanoma (I to IV) and is proposed as a prognostic
biomarker for the disease (Findeisen et al., 2009). Different types
of cancers occur less frequently in PD patients, however the risk
of melanoma is about 2-fold higher than in general population
(Liu et al., 2011). These findings corroborate the role of SAA
within the pathomechanistic link between melanoma and PD.
It would be of interest to measure the levels of keratinocyte-
derived SAA in patients diagnosed with both PD and melanoma
to elaborate these findings.
SAA as an Intrinsically Disordered
Protein
Intrinsically disordered proteins (IDPs) refer to proteins
without fixed three-dimensional structures under physiological
conditions, allowing the same polypeptide to undertake different
interactions with different consequences (Zhang et al., 2013).
This lack of proper fixed structure enables IDPs to interact with
many ligands, but renders them vulnerable to environmental
changes and causes them to misfold. IDPs are involved in
neurodegenerative diseases (Uversky, 2009, 2015), which all
exhibit characteristic accumulation of incorrectly folded proteins
that hence form insoluble deposits (Takalo et al., 2013). SAA is
an IDP (Ye et al., 2011; Colón et al., 2015) and therefore able to
contribute to protein deposit formation in PD. Overexpression
of IDPs, like a-synuclein, in the CNS is known to cause
neurodegeneration in model organisms (Kirik and Björklund,
2003). It is suggestive that SAA acts similarly in the CNS of PD. In
a mouse model of AD, systemic LPS was administered (Liu et al.,
2016), which induced SAA expression that led to activation of
brain microglia and to suppression of tau hyperphosphorylation,
having a modifying effect on neurofibrillary tangle development.
Acute SAA is shown to be elevated in human AD brains
(Liang et al., 1997) and cerebrospinal fluid (Kindy et al., 1999).
Neurodegenerative diseases, like AD and PD are associated with
neuroinflammation, suggesting that also the levels of SAA, as one
of acute phase reactants, are expected to be higher in the CNS.
How SAA acts in the periphery in neurodegenerative diseases
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is largely unknown. We now show that SAA is downregulated
in the peripheral tissues like skin and blood, which could be a
compensatory effect for excessive levels of aberrant SAA in the
CNS.
Global Peripheral Downregulation of SAA
Protein
Within this study we have also demonstrated significantly
lowered protein levels of SAA in PD serum. This finding suggests
that the downregulation of SAA proteins occurs in PD patients
not only on the transcriptomic level in the skin, but more
globally also in other tissues. Liver is the predominant synthesis
place of SAA, from where SAA proteins are secreted into the
circulation. The downregulated levels in serum indicate a reduced
transcription of SAA in the liver tissue. In the skin, no SAA could
be detected using immunohistochemistry and by Western blot
method. This was expected, as the accumulation of misfolded
SAA is known as AA-Amyloidosis and it seems to appear in the
conditions of chronic inflammation with elevated serum levels
of SAA. We showed, instead, downregulated levels of SAA in
both skin and serum. In the normal brain tissue, SAA is not
detectable, but it has been shown to be elevated in the CNS under
induced inflammatory conditions and in case of Alzheimer’s
disease (Liang et al., 1997; Guo et al., 2002). How SAA acts in the
CNS in case of PD and whether its expression in the periphery
affects it, is largely unknown. We have now characterized the
downregulation of SAA in PD skin and serum and demonstrated
that no visible deposits of SAA protein in the skin of PD patients
can be seen.
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